Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 32 studies | 37% ± 16% | |
fibroblast | 16 studies | 39% ± 15% | |
smooth muscle cell | 13 studies | 25% ± 8% | |
astrocyte | 13 studies | 54% ± 18% | |
oligodendrocyte | 12 studies | 31% ± 7% | |
microglial cell | 11 studies | 24% ± 7% | |
endothelial cell of lymphatic vessel | 10 studies | 41% ± 17% | |
adipocyte | 10 studies | 79% ± 14% | |
T cell | 9 studies | 33% ± 11% | |
B cell | 9 studies | 31% ± 13% | |
vein endothelial cell | 9 studies | 38% ± 25% | |
macrophage | 8 studies | 28% ± 8% | |
CD4-positive, alpha-beta T cell | 7 studies | 33% ± 15% | |
endothelial cell of artery | 7 studies | 32% ± 17% | |
regulatory T cell | 7 studies | 34% ± 17% | |
oligodendrocyte precursor cell | 7 studies | 29% ± 9% | |
pericyte | 6 studies | 23% ± 5% | |
epithelial cell | 6 studies | 35% ± 16% | |
myofibroblast cell | 6 studies | 32% ± 15% | |
CD8-positive, alpha-beta T cell | 6 studies | 24% ± 7% | |
GABAergic neuron | 5 studies | 23% ± 3% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 5 studies | 30% ± 11% | |
lymphocyte | 5 studies | 36% ± 18% | |
endothelial cell of vascular tree | 5 studies | 37% ± 18% | |
monocyte | 5 studies | 30% ± 8% | |
hepatocyte | 4 studies | 66% ± 28% | |
cardiac muscle cell | 4 studies | 30% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 4 studies | 28% ± 11% | |
mast cell | 4 studies | 26% ± 13% | |
ciliated cell | 4 studies | 31% ± 12% | |
myeloid cell | 4 studies | 29% ± 8% | |
retinal rod cell | 4 studies | 25% ± 5% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 18% ± 3% | |
basal cell | 4 studies | 27% ± 6% | |
endothelial cell of sinusoid | 3 studies | 38% ± 12% | |
hepatic stellate cell | 3 studies | 46% ± 14% | |
plasma cell | 3 studies | 29% ± 11% | |
pro-B cell | 3 studies | 22% ± 4% | |
endocardial cell | 3 studies | 39% ± 15% | |
mucosal invariant T cell | 3 studies | 32% ± 9% | |
capillary endothelial cell | 3 studies | 31% ± 9% | |
neuron | 3 studies | 42% ± 22% | |
cholangiocyte | 3 studies | 49% ± 24% | |
mature NK T cell | 3 studies | 34% ± 18% | |
connective tissue cell | 3 studies | 30% ± 13% | |
ependymal cell | 3 studies | 46% ± 20% | |
adventitial cell | 3 studies | 28% ± 12% | |
alveolar macrophage | 3 studies | 32% ± 7% | |
club cell | 3 studies | 24% ± 9% | |
natural killer cell | 3 studies | 23% ± 1% | |
naive B cell | 3 studies | 24% ± 8% | |
Schwann cell | 3 studies | 63% ± 14% | |
dendritic cell | 3 studies | 24% ± 6% | |
mucus secreting cell | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 4889.27 | 652 / 653 | 100% | 29.39 | 604 / 605 |
ovary | 100% | 13826.84 | 180 / 180 | 99% | 16.92 | 426 / 430 |
lung | 100% | 4884.28 | 577 / 578 | 98% | 16.18 | 1135 / 1155 |
uterus | 100% | 9376.16 | 170 / 170 | 98% | 16.47 | 449 / 459 |
prostate | 98% | 3035.02 | 241 / 245 | 99% | 11.74 | 499 / 502 |
breast | 100% | 7973.93 | 459 / 459 | 98% | 14.08 | 1091 / 1118 |
intestine | 100% | 3487.73 | 966 / 966 | 97% | 13.66 | 513 / 527 |
bladder | 100% | 3834.19 | 21 / 21 | 97% | 12.43 | 487 / 504 |
esophagus | 96% | 3727.83 | 1389 / 1445 | 99% | 20.16 | 181 / 183 |
skin | 98% | 4202.57 | 1766 / 1809 | 96% | 15.67 | 453 / 472 |
kidney | 94% | 1955.92 | 84 / 89 | 97% | 14.27 | 872 / 901 |
pancreas | 88% | 1639.97 | 289 / 328 | 99% | 25.41 | 176 / 178 |
liver | 90% | 2036.81 | 204 / 226 | 96% | 10.98 | 388 / 406 |
stomach | 79% | 2091.23 | 285 / 359 | 98% | 16.25 | 279 / 286 |
adrenal gland | 98% | 2163.32 | 254 / 258 | 67% | 7.25 | 153 / 230 |
brain | 53% | 1029.22 | 1400 / 2642 | 100% | 19.40 | 702 / 705 |
adipose | 100% | 9350.79 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 27.17 | 29 / 29 |
spleen | 100% | 2862.23 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.64 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.35 | 1 / 1 |
blood vessel | 100% | 4271.33 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 14889.29 | 796 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 91% | 7.97 | 73 / 80 |
heart | 86% | 2072.76 | 737 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 48% | 830.37 | 443 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000177 | Biological process | regulation of neural precursor cell proliferation |
GO_0097009 | Biological process | energy homeostasis |
GO_1903243 | Biological process | negative regulation of cardiac muscle hypertrophy in response to stress |
GO_2000377 | Biological process | regulation of reactive oxygen species metabolic process |
GO_0097150 | Biological process | neuronal stem cell population maintenance |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0070542 | Biological process | response to fatty acid |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0006974 | Biological process | DNA damage response |
GO_0045599 | Biological process | negative regulation of fat cell differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0009267 | Biological process | cellular response to starvation |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0001678 | Biological process | intracellular glucose homeostasis |
GO_0046676 | Biological process | negative regulation of insulin secretion |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_0071732 | Biological process | cellular response to nitric oxide |
GO_0034393 | Biological process | positive regulation of smooth muscle cell apoptotic process |
GO_0070417 | Biological process | cellular response to cold |
GO_0032873 | Biological process | negative regulation of stress-activated MAPK cascade |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0045722 | Biological process | positive regulation of gluconeogenesis |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0060260 | Biological process | regulation of transcription initiation by RNA polymerase II |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_0001568 | Biological process | blood vessel development |
GO_0071455 | Biological process | cellular response to hyperoxia |
GO_0006915 | Biological process | apoptotic process |
GO_0001659 | Biological process | temperature homeostasis |
GO_0006914 | Biological process | autophagy |
GO_0010467 | Biological process | gene expression |
GO_0006473 | Biological process | protein acetylation |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045444 | Biological process | fat cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005739 | Cellular component | mitochondrion |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0051721 | Molecular function | protein phosphatase 2A binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_1990841 | Molecular function | promoter-specific chromatin binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0003676 | Molecular function | nucleic acid binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FOXO1 |
Protein name | Alternative protein FOXO1 Forkhead box protein O1 (Forkhead box protein O1A) (Forkhead in rhabdomyosarcoma) |
Synonyms | FKHR FOXO1A |
Description | FUNCTION: Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress . Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3' . Activity suppressed by insulin . Main regulator of redox balance and osteoblast numbers and controls bone mass (By similarity). Orchestrates the endocrine function of the skeleton in regulating glucose metabolism (By similarity). Also acts as a key regulator of chondrogenic commitment of skeletal progenitor cells in response to lipid availability: when lipids levels are low, translocates to the nucleus and promotes expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation (By similarity). Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity (By similarity). Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP (By similarity). Acts as an inhibitor of glucose sensing in pancreatic beta cells by acting as a transcription repressor and suppressing expression of PDX1 (By similarity). In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC1 and PCK1 (By similarity). Also promotes gluconeogenesis by directly promoting expression of PPARGC1A and G6PC1 . Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1 . Promotes neural cell death . Mediates insulin action on adipose tissue (By similarity). Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake (By similarity). Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells (By similarity). Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner . Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By similarity). Positive regulator of apoptosis in cardiac smooth muscle cells as a result of its transcriptional activation of pro-apoptotic genes . Regulates endothelial cell (EC) viability and apoptosis in a PPIA/CYPA-dependent manner via transcription of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis . . |
Accessions | ENST00000379561.6 Q12778 L8E9Y8 |